GLPG1690 from Galapogas, receives orphan drug designation for idiopathic pulmonary fibrosis
Release Date: 13-Oct-2016
Galapogas, a Belgium based drug developing company, has received orphan drug status for GLPG1690 to treat patients suffering from idiopathic pulmonary fibrosis, in Europe. GLPG1690 has unique approach to target a novel molecule, GPR84, a pro-inflammatory protein responsible for chronic low grade inflammatory diseases targets a novel molecule, GPR84, a pro-inflammatory protein responsible for chronic low grade inflammatory diseases.
The drug yielded a positive result in efficacy, safety, and tolerability in phase 1 clinical investigation.
Pulmonary fibrosis is a lung damaging disease including thick, stiff and scarred lungs. Affected lungs are not able to pump oxygen all over the body, as a result, the human brain does not receives the required oxygen.
For Orphan Drug Clinical Insight Reports Contact: email@example.com
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.